Liver Transplant Clinical Trial
Official title:
Targeting Trimethylamine N-Oxide for Cardiovascular Health In Liver Transplant Recipients
Despite medical and surgical advances, long-term survival in liver transplant (LT) recipients is compromised by an increased risk of cardiovascular disease (CVD) after transplant, the mechanisms of which are still not fully understood. TMAO is an attractive therapeutic target to improve vascular health and diastolic function toward preventing CVD in LT patients. Therefore, the purpose of this study is to better understand the role of TMAO in cardiovascular dysfunction patients with chronic kidney disease.
Despite medical and surgical advances, long-term survival in liver transplant (LT) recipients is compromised by an increased risk of cardiovascular disease (CVD) after transplant, the mechanisms of which are still not fully understood. Following LT, patients have an increased incidence of atherosclerotic CVD. Notably, atherosclerotic CVD is an established risk factor for diastolic dysfunction and incident heart failure with preserved ejection fraction (HFpEF). There is a critical need to better understand the biological mechanisms of LT related vascular dysfunction and establish targeted interventions that will reduce the risk of CVD in this patient population. In the general population, there is strong epidemiological evidence linking high TMAO levels with atherosclerotic CVD and heart failure, and that it can modulated rapidly by diet within two weeks. Therefore, the purpose of this study is to better understand the role of TMAO in cardiovascular dysfunction patients with chronic kidney disease. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02798861 -
Controlled Attenuation Parameter (CAP) in Liver Allografts
|
||
| Completed |
NCT03527238 -
Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine
|
Phase 2 | |
| Completed |
NCT01696331 -
Text Messaging for Adherence in Adolescent Liver Transplant Recipients
|
N/A | |
| Recruiting |
NCT05051605 -
Immune Response to COVID-19 Vaccine in Recipients of Living Donor Liver Transplantation
|
||
| Recruiting |
NCT05940857 -
Sponsor-Initiated OCS Liver Perfusion (OLP-II) Registry
|
||
| Completed |
NCT01598987 -
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
|
Phase 3 | |
| Active, not recruiting |
NCT05074160 -
OCS Liver Perfusion (OLP) Post-Approval Registry
|
||
| Completed |
NCT05087550 -
Multicenter Study on Organ Acquisition Costs in the Post Re-Allocation Era: Liver Transplantation
|
||
| Recruiting |
NCT04836923 -
LIFT Intervention in Liver Transplant Candidates
|
N/A | |
| Not yet recruiting |
NCT03666689 -
Outflow Reconstruction in Right Lobe Living Donor Liver Transplantation
|
||
| Not yet recruiting |
NCT06088758 -
Normothermic Machine Perfusion of Steatotic Livers for Expansion of Donor Organ Pool
|
N/A | |
| Terminated |
NCT01230502 -
Mycophenolic Acid (MPA) Monotherapy in Liver Transplantation
|
N/A | |
| Completed |
NCT00171509 -
Efficacy and Safety of Cyclosporine Microemulsion Given Once a Day in Adult Stable Liver Transplant Recipients
|
Phase 4 | |
| Not yet recruiting |
NCT06254248 -
Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma
|
Phase 2 | |
| Recruiting |
NCT06075745 -
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates
|
Phase 2 | |
| Completed |
NCT02057484 -
A 5 Year Follow-up of Patients Who Were Previously Enrolled Into an Advagraf Trial Following a Liver or Kidney Transplant
|
||
| Active, not recruiting |
NCT03577431 -
Liver Transplantation With Tregs at MGH
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06342557 -
Transitional ePRO Diary Liver
|
||
| Not yet recruiting |
NCT04265157 -
Hepato-duodenal Ligament Occlusion and Classic Technique in Liver Transplant
|
||
| Recruiting |
NCT02863250 -
Australian and New Zealand Massive Transfusion Registry
|